1. Introduction

The National Diabetes Register (NDR) has been collecting information about people who have begun to use insulin to manage their diabetes since 1 January 1999. This is the second statistical profile on the Register. The NDR was established following the launch of the National Diabetes Strategy and Implementation Plan in June 1998 (Colagiuri et al. 1998). As part of this strategy, the Ministerial Advisory Committee on Diabetes (MACOD) recommended the establishment of a National Diabetes Register for people with insulintreated diabetes.

In August 1998, the AIHW was contracted to operate the Register by the then Commonwealth Department of Health and Aged Care. The Register has two main data sources—the National Diabetes Services Scheme (NDSS) database, administered by Diabetes Australia, and the Australasian Paediatric Endocrine Group (APEG) state-based databases.

Registration on the National Diabetes Register is not determined by a person's type of diabetes, but by whether or not insulin is used to treat the diabetes. A person is eligible for the Register if insulin use commenced on or after 1 January 1999. Currently it includes new cases of insulin-treated diabetes mellitus from 1 January 1999 where consent has been provided for inclusion on the Register.

A person is not eligible for the Register if:

- insulin use commenced before 1 January 1999;
- insulin is not used to treat the person's diabetes; or
- consent is not provided.

Thus the Register includes people with all types of diabetes (Type 1, Type 2, gestational diabetes and other forms of diabetes) who are insulin-using and who have consented to be on the Register.

Structure and content of this report

This report has been divided into seven parts. Following this Introduction, Chapter 2 summarises the Register's holdings. Chapter 3 focuses on persons with Type 1 diabetes while Chapter 4 examines persons with other types of insulin-treated diabetes excluding Type 1. Chapter 5 looks at the mortality of the NDR registrants and Chapter 6 contains statistical notes relevant to the analyses performed on the NDR data to produce this report. Chapter 7 provides details for researchers wanting to access the NDR data for diabetes research

2. Summary of Register data

The primary source of records of insulin-treated diabetes mellitus (ITDM) in Australia is the National Diabetes Services Scheme (NDSS). Secondary sources are the research databases of the Australasian Paediatric Endocrine Group (APEG) for 0–14 year olds and the Tasmanian Insulin Treated Diabetes Register which is held at the Menzies Centre for Population Health in Hobart.

2.1 Age and sex

The age distribution of the Register shows a pattern of increasing numbers with age, particularly after 45 years when numbers increase sharply. More than 60% of registrants are aged 45 years and over, compared with less than 10% aged under 15 years (Table 2.1).

There is a slightly higher proportion of male records on the Register (50.3%) compared to female records (49.7%). However, these proportions vary considerably with age. For the younger age groups, the ratio of male to female records is similar. In the 25–34 and 35–44 age groups, females strongly outnumber males, reflecting the effect of gestational diabetes in women from these age groups.

For older age groups (45–74 years), males strongly outnumber females, with 32% more male registrants than females. This may be attributed to lifestyle differences between males and females. The 1995 National Nutrition Survey showed that at every adult age, men were more likely than women to be overweight or obese, a major risk factor for diabetes (ABS 1998a). This survey also showed that mean waist-to-hip ratios were higher in men than women and increased with age. High waist-to-hip ratios indicate excessive abdominal fat which is associated with increased risk of diabetes.

For the ages 75 and over, there are 8% more females on the Register than males. This reflects the substantially lower proportion of males in the population in this age group due to the higher female life expectancy.

New cases of persons requiring insulin to treat their diabetes predominantly occur among middle-aged and older men with Type 2 diabetes, women in their twenties and thirties with gestational diabetes, and in older women with Type 2 diabetes.

Table 2.1: NDR registrants: current age and sex, 1999-2001

Age at 31 December 2001	Males	Females	Total	% Male
		Number	•	
0–4	184	138	322	57.1
5–9	379	357	736	51.5
10–14	518	514	1,032	50.2
15–24	655	597	1,252	52.3
25–34	751	1,635	2,386	31.5
35–44	966	1,466	2,432	39.7
45–54	1,708	1,243	2,951	57.9
55–64	2,246	1,620	3,866	58.1
65–74	2,078	1,695	3,773	55.1
75 and over	1,247	1,349	2,596	48.0
Total	10,732	10,614	21,346	50.3
		Per cent		
0–4	0.9	0.6	1.5	n.a.
5–9	1.8	1.7	3.4	n.a.
10–14	2.4	2.4	4.8	n.a.
15–24	3.1	2.8	5.9	n.a.
25–34	3.5	7.7	11.2	n.a.
35–44	4.5	6.9	11.4	n.a.
45–54	8.0	5.8	13.8	n.a.
55–64	10.5	7.6	18.1	n.a.
65–74	9.7	7.9	17.7	n.a.
75 and over	5.8	6.3	12.2	n.a.
Total	50.3	49.7	100.0	n.a.

Note: Deceased registrants have been excluded from this table.

2.2 Geographical location

The age-standardised registration rates (expressed as per 100,000 population) for 1999–2001 across metropolitan, rural and remote areas of Australia are similar for most states and territories (Table 2.2). The exceptions are South Australia and the Northern Territory, due to lower ascertainment—in remote areas of South Australia and the Northern Territory, diabetes products may be obtained from remote area pharmacy services which are not part of the NDSS. As a result the NDR does not receive data from these people.

Table 2.2: NDR registrants: geographical locations, (a) states and territories, 1999-2001

-	Metro	opolitan		Rural			
state/ territory	Capital city	Other metropolitan	Large rural centres	Small rural centres	Other rural areas	Remote	Total
				Number			
NSW	4,563	1,036	340	590	881	79	7,488
Vic	4,196	218	378	378	744	21	5,935
Qld	1,954	597	592	264	684	270	4,362
WA	1,704	_	_	248	301	259	2,512
SA	817	_	26	94	216	18	1,170
Tas	245	_	124	83	171	4	627
ACT	376	_	_	_	_	_	376
NT	51	_	_	_	9	46	105
Total	13,904	1,852	1,460	1,657	3,006	696	22,575
		Average a	nnual age-standa	rdised rate (pe	r 100,000 popul	ation) ^{(b)(c)}	
NSW	36.2	38.6	34.5	36.8	36.9	44.6	36.1
Vic	38.7	42.2	52.9	42.6	35.9	47.4	39.1
Qld	40.2	38.5	39.7	35.5	38.8	48.6	39.7
WA	40.7	_	_	55.6	51.1	54.6	43.9
SA	23.8	_	35.3	35.4	23.8	22.0	24.3
Tas	39.9	_	46.3	43.2	40.0	51.1	41.4
ACT	42.6	_	_	_	_	_	42.6
NT	21.2	_	_	_	26.6	22.9	21.6
Total	36.9	39.0	41.1	40.0	36.6	45.5	37.4

⁽a) Registrants are classified into metropolitan, rural and remote zones according to the Rural, Remote and Metropolitan Areas Classification (DPIE & DHSH 1994).

2.3 Type of diabetes

Type of diabetes is reported on the NDSS registration form by either a medical practitioner or an accredited diabetes educator. In the APEG collection, diabetes type is nearly always certified by a medical specialist. In making the NDR, the NDSS and APEG records are merged and deduplicated. When a difference in diabetes type is found, the certification by the health professional with the highest qualification is included in the Register. In age groups older than 14 years of age, where there is no source of secondary ascertainment, the diabetes type reported by the NDSS is accepted. However, it has been found that a concerning proportion of registrants on the NDR have been recorded as having Type 1 diabetes when they actually have Type 2 diabetes (AIHW 2001:13).

In order to obtain a more accurate measure of type of diabetes, an algorithm has been developed which re-classifies registrants with reported Type 1 diabetes over the age of 35

⁽b) The population at 30 June 2000 by geographic location is used to derive the standardised rate (see Chapter 6).

⁽c) Age-standardised to the Australian population at 30 June 1991. The direct method of standardisation is used (see Chapter 6).

years. The algorithm is based on age at diagnosis and the period of time between diagnosis and date of first insulin use (for more information on the algorithm, see Section 6.2).

Table 2.3 shows data for the NDR registrants before (reported) and after (derived) the algorithm was applied. It can be seen that under the ages of 35 years the number of registrants with Type 1 diabetes remains the same regardless of whether the type of diabetes is reported or derived. This is because the algorithm does not apply to registrants under the age of 35. However, in each of the age groups 35 years and above, the number of registrants with Type 1 diabetes falls dramatically after the algorithm is applied. For example, in the age groups of 35–44 years the number of registrants with reported Type 1 diabetes is 906 but the derived type of diabetes shows only 633 with Type 1 diabetes in this age group.

In total the algorithm re-classified 1,824 people who were originally reported as having Type 1 diabetes. Of these people, 1,434 were re-classified as Type 2. For the remaining 390 people, a type of diabetes could not be derived due to missing information, such as date of first insulin use. Clearly, the algorithm helps to reduce the misrepresentation of the level of Type 1 diabetes on the register. For this reason tables in this report involving type of diabetes are based on derived type of diabetes and not reported type of diabetes, unless otherwise stated. However, it should be noted that the algorithm cannot re-classify all records that have been misreported and thus the breakdown of diabetes type in this report may not reflect the true distribution of diabetes type among people with insulin-treated diabetes.

Table 2.3: NDR registrants: reported and derived(a) diabetes type, by age, 1999-2001

		Reported	I diabetes type		Derived diabetes type					
Age at diagnosis	Type 1	Type 2	Gestational	Other	Type 1	Type 2	Gestational	Other		
0–4	490	5	_	9	490	5	_	9		
5–9	819	8	_	8	819	8	_	8		
10–14	1,004	27	1	21	1,004	27	1	21		
15–24	1,010	234	131	27	1,010	234	131	27		
25–34	995	933	1,017	38	995	933	1,017	38		
35–44	906	2,131	448	40	633	2,404	448	40		
45–54	923	3,082	7	61	466	3,540	6	61		
55–64	903	2,643	1	55	480	3,067	_	55		
65–74	590	1,584	2	28	371	1,805	_	28		
75 and over	356	690	1	13	294	753	_	13		
Not stated	436	830	55	13	46	831	54	13		
Total	8,432	12,167	1,663	313	6,608	13,607	1,657	313		

⁽a) Type of diabetes could not be derived for 390 registrants due to missing information.

The Register contains 22,575 records for people who commenced using insulin between 1 January 1999 and 31 December 2001 (Table 2.4). There were 11,462 males and 11,113 females. Using derived type of diabetes, 33% of males had Type 1 diabetes compared with 25% of females; and 15.0% of females were reported to have gestational diabetes.

Table 2.4: NDR registrants: derived diabetes type, by sex, 1999-2001

	Males		Fema	les	Perso	ns
	Number	Per cent	Number	Per cent	Number	Per cent
Type 1	3,780	33.0	2,828	25.4	6,608	29.3
Type 2	7,322	63.9	6,285	56.6	13,607	60.3
Gestational			1,657	14.9	1,657	7.3
Other types ^(a)	170	1.5	143	1.3	313	1.4
Not derived ^(b)	190	1.7	200	1.8	390	1.7
Total	11,462	100.0	11,113	100.0	22,575	100.0

⁽a) See Glossary for other types of diabetes.

2.4 Mortality

Register records were matched with the National Death Index (NDI). For the years 1999–2001, there were 1,229 registrants identified as having died, representing 5.4% of Register holdings (Table 2.5). Nineteen per cent of deaths were for registrants with Type 1 diabetes. The largest proportion of registrants recorded as deceased was in Tasmania (6.9%).

Table 2.5: NDR registrants: vital status and derived^(a) type of diabetes, by states and territories, 1999–2001

Vital status	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Australia
Alive	7,087	5,584	4,129	2,399	1,101	584	358	104	21,346
Type 1	2,175	1,521	1,098	736	495	201	110	37	6,373
Other types	4,734	3,998	2,984	1,645	586	376	246	66	14,635
Deceased	401	351	233	113	69	43	18	1	1,229
Type 1	93	55	31	21	21	9	5	0	235
Other types	279	281	197	91	46	34	13	1	942
Total	7,488	5,935	4,362	2,512	1,170	627	376	105	22,575

⁽a) Type of diabetes could not be derived for 390 registrants due to missing information; however, they are included in the totals.

2.5 Indigenous status

Just over 2% of records on the Register are for persons who report being of Aboriginal or Torres Strait Islander origin (Table 2.6). This percentage is consistent with the proportion of Indigenous people in the Australian population (2.2% in 2001). Although consistent with the population, the Register is likely to significantly under-report the true level of Indigenous people with insulin-treated diabetes because:

 the NDSS does not receive data from people who purchase diabetes products through remote area pharmacy services—many of these people are Indigenous people who inhabit remote areas; and

⁽b) A derived diabetes type could not be calculated due to missing date of first injection or missing date of diagnosis.

the NDSS form is believed to obtain inadequate identification of Indigenous status.
Incorrectly reporting Indigenous status particularly occurs if the personal details have been completed on the form by someone other than the registrant, e.g. a doctor or diabetes educator.

Proportions of Indigenous registrants differed among states and territories, the highest being in the Northern Territory (39.0%), the lowest in Victoria and the Australian Capital Territory (both 0.3%).

It is important to note that Register numbers do not reflect the higher prevalence or incidence of diabetes in Indigenous Australians. Prevalence of diabetes (mainly Type 2) is considerably higher among Aboriginal and Torres Strait Islander people than for the whole Australian community (AIHW 2002a). Available data suggest that overall prevalence lies between 10% and 30% of the Aboriginal and Torres Strait Islander peoples population and is therefore likely to be 2–4 times that of the non-Aboriginal community (De Courten et al. 1998).

Table 2.6: NDR registrants: Indigenous status, by age at first insulin use, states and territories, 1999–2001

	NSW	Vic	Qld	WA	SA	Tas	ACT	NT	Australia
Age at first insulin use									
0–14									
Indigenous	18	3	6	8	_	3	_	2	40
Non-Indigenous	722	228	367	241	182	57	40	11	1,848
Not stated	43	339	79	1	7	2	_	2	473
15–34									
Indigenous	22	3	38	27	2	4	_	13	109
Non-Indigenous	1,145	840	733	374	208	103	95	14	3,512
Not stated	63	18	6	10	4	9	1	_	111
35–54									
Indigenous	33	4	72	78	2	10	1	17	217
Non-Indigenous	1,750	1,350	1,045	623	260	123	111	15	5,277
Not stated	109	27	13	16	10	8	3	3	189
55 and over									
Indigenous	29	8	29	36	5	3	_	9	119
Non-Indigenous	3,366	3,054	1,962	1,066	461	279	123	17	10,328
Not stated	188	61	12	32	29	26	2	2	352
Total persons	7,488	5,935	4,362	2,512	1,170	627	376	105	22,575

2.6 Country of birth

There is substantial variation in the registration rate by birthplace (Table 2.7). The number of registrants per 100,000 population is highest among those born in North Africa and the Middle East and Southern and Central Asia. Both these groups have registration rates substantially higher than those of the Australian-born registrants, being more than 50%

higher for males and more than double for females. All other birthplace groups show similar registration rates to those for the Australian-born population.

The median age at diagnosis ranged between 41 and 47 for most countries of birth, with the exceptions of North-West Europe and Southern and Eastern Europe groups, which have a median age at diagnosis in the mid-50s.

Table 2.7: NDR registrants aged 15 years and over at diagnosis: country of birth, sex and median age at diagnosis, 1999–2001

	Male	es	Fe	males	
Country of birth ^(a)	Number	Average annual rate ^(b) per 100,000 population	Number	Average annual rate ^(b)	Median age at diagnosis (years)
Australia	6,713	43.5	6,629	39.5	47.2
Oceania and Antarctica (excluding Australia)	244	41.9	326	53.4	40.6
North-West Europe	909	31.7	757	29.3	55.1
Southern and Eastern Europe	1,344	56.3	1,050	50.3	56.4
North Africa and the Middle East	267	73.4	276	88.0	47.2
South-East Asia	223	49.8	337	52.4	45.4
North-East Asia	134	39.6	213	50.9	45.5
Southern and Central Asia	200	72.7	242	92.5	41.3
Americas	98	42.7	82	38.6	44.3
Sub-Saharan Africa	86	49.8	75	39.2	43.5

⁽a) Country of birth refers to ABS Standard Australian Classification of Countries—major groups (ABS 1998b).

⁽b) Age-standardised to the Australian population at 30 June 1991.

3. Persons with Type 1 diabetes

This chapter focuses on data for registrants with Type 1 diabetes aged under 40 years. In the previous statistical profile, AIHW reported on difficulties in the accurate classification of diabetes types (AIHW 2001). Correct classification of diabetes type for those aged 40 years and over is clinically difficult and inaccuracies may be reflected in the NDR data.

For those aged 0–14 years, dual ascertainment and certification from a specialist is considered sufficient to provide accurate classification of diabetes type. Because of this, and because coverage is believed to be close to 100%, the younger age groups have reliable estimates of Type 1 diabetes incidence.

Dual ascertainment is not available for those aged 15–39, and misclassification of diabetes type can occur, particularly by non-specialist practitioners who may wrongly assume that requirement for insulin in this age group means that the person has Type 1 diabetes. However, advice from the NDR Management Committee suggests that almost all Type 1 registrants in this age group are correctly classified and the high costs that would be incurred in investigating this matter further by checking against medical records are not justified.

3.1 New cases of Type 1 diabetes under 40 years of age

Features of NDR registrants aged 0–39 years with Type 1 diabetes were as follows:

- There were 4,548 new cases for the three years 1999–2001—2,587 (56.9%) were males and 1,961 (43.1%) were females (Table 3.1). This represents 69% of NDR registrants with Type 1 diabetes; the remaining 31% (2,060) were aged 40 and over (derived from Table 2.3).
- Tasmanians reported the highest average rate of new cases per year (18.1 per 100,000 population) (Table 3.2).
- The geographic distribution of new cases with Type 1 diabetes aged 0–39 years was 61.3% in capital cities, 8.2% in other metropolitan areas, 6.6% in large rural centres, 7.1% in small rural centres, and 16.7% in other rural areas and remote areas (Table 3.3). However, remote areas are known to be relatively under-represented because of distribution of diabetes services products through remote area pharmacy services rather than through the NDSS.

Table 3.1: NDR registrants aged 0–39 years with derived $^{(a)}$ Type 1 diabetes, by age and sex, 1999–2001

	Males		Fema	iles	Persons		
Age at first insulin use	Number	Per cent	Number	Per cent	Number	Per cent	
0–14	1,207	46.7	1,092	55.7	2,299	50.5	
15–24	570	22.0	389	19.8	959	21.1	
25–39	810	31.3	480	24.5	1,290	28.4	
Total	2,587	100.0	1,961	100.0	4,548	100.0	

⁽a) There is no difference between reported and derived type of diabetes for registrants aged 0–35 years (see Table 2.3).

Table 3.2: NDR registrants aged 0–39 years with derived $^{(a)}$ Type 1 diabetes: states and territories, 1999–2001

Year of first insulin use	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
msum use	NOW	VIC	Qiu	- JA	Number	Tas	141	ACT	Australia
					Number				
1999	454	376	293	91	183	45	10	35	1,487
2000	504	323	290	123	160	46	7	25	1,478
2001	492	375	321	116	181	50	10	38	1,583
Total	1,450	1,074	904	330	524	141	27	98	4,548
			Number p	per 100,000	population	aged 0-39 y	years ^(b)		
1999	12.3	13.9	14.1	11.1	16.6	17.3	7.3	18.1	13.5
2000	13.6	11.9	14.0	15.0	14.5	17.7	5.1	12.9	13.4
2001	13.3	13.8	15.4	14.1	16.4	19.2	7.3	19.6	14.4
		Avera	ge annual n	umber per	100,000 po	pulation age	ed 0–39 yea	ars ^(b)	
1999–2001	13.1	13.2	14.5	13.4	15.8	18.1	6.5	16.9	13.8

⁽a) There is no difference between reported and derived type of diabetes for registrants aged 0–35 years (see Table 2.3).

⁽b) Population is at 30 June 2000.

Table 3.3: NDR registrants aged 0-39 years with derived^(a) Type 1 diabetes: geographical locations,^(b) 1999-2001

		Age at first insulin us	e (years)	
Geographical location	0–14	15–24	25–39	Total
		Number		
Capital city	1,361	617	810	2,788
Other metropolitan	203	68	102	372
Large rural centre	144	66	91	302
Small rural centre	175	57	93	325
Other rural and remote	416	150	195	762
Total Australia	2,299	959	1,290	4,548
		Per cent		
Capital city	59.2	64.3	62.8	61.3
Other metropolitan	8.8	7.1	7.9	8.2
Large rural centre	6.3	6.9	7.0	6.6
Small rural centre	7.6	6.0	7.2	7.1
Other rural and remote	18.1	15.7	15.1	16.7
Total Australia	100.0	100.0	100.0	100.0

⁽a) There is no difference between reported and derived type of diabetes for registrants aged 0-35 years (see Table 2.3).

3.2 Incidence estimates for 0-14 year olds

NDR records for 0–14 year olds were received from three data sources:

- Diabetes Australia:
- APEG; and
- Menzies Centre in Tasmania.

As a result, coverage of new cases of insulin-treated diabetes under 15 years of age is considered to be close to 100% for 2000 and 2001.

Features of the Type 1 diabetes incidence for 0–14 year olds were as follows:

- New cases of Type 1 diabetes for male children were on average 20.3 new registrations per 100,000 population per year; the corresponding number for female children was 18.9 (Table 3.4).
- For most states and territories, rates were lower in the younger age groups (0–4 years) than in the 5–9 or 10–14 year groups. Care should be taken when interpreting these rates for the smaller states and territories due to the small numbers involved.
- The numbers of new cases remained similar across 1999, 2000 and 2001 for most states and territories, with cases in 2001 showing a general increase (Table 3.5).
- Australia is among the moderate to high incidence countries, see next section.

⁽b) Registrants are classified according to the Rural, Remote and Metropolitan Areas Classification (DPIE & DHSH 1994).

Table 3.4: New cases of Type 1 diabetes among 0–14 year olds: sex and age, states and territories, 2000 and 2001

Sex and age at first insulin use	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
					Numbe				
Males									
0–4	55	45	39	13	22	7	_	6	187
5–9	89	69	58	23	25	10	1	4	279
10–14	137	73	73	34	29	9	4	6	365
Total males 0–14	281	187	170	70	76	26	5	16	831
Females									
0–4	50	34	32	8	13	2	1	3	143
5–9	87	75	49	26	31	8	_	4	280
10–14	100	80	59	28	33	7	_	4	311
Total females 0–14	237	189	140	62	77	17	1	11	734
			Av	erage annu	al rate per 1	00,000 popu	ılation		
Males									
0–4	12.2	14.1	15.3	13.7	16.8	21.8	_	28.1	14.2
5–9	19.0	20.6	21.5	22.5	18.0	28.8	_	17.7	20.1
10–14	29.6	22.0	27.3	32.7	20.2	25.4	_	26.0	26.4
Total males 0–14	20.4	19.0	21.5	23.2	18.4	25.5	_	23.9	20.3
Females									
0–4	11.7	11.2	13.3	8.8	10.4	6.6	_	14.5	11.4
5–9	19.6	23.5	19.2	26.8	23.6	24.3	_	18.3	21.2
10–14	22.7	25.1	23.4	28.6	24.3	20.9	_	18.1	23.6
Total females 0–14	18.1	20.1	18.7	21.7	19.7	17.5	_	17.0	18.9

Table 3.5: New cases of Type 1 diabetes among 0-14 year olds: states and territories, 1999, 2000, 2001

Year	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
1999	237	172	135	57	84	18	4	13	720
2000	247	174	150	73	69	16	1	13	743
2001	271	202	160	59	84	27	5	14	822

International comparison

Australia is among the countries with a moderate to high incidence for children diagnosed with Type 1 diabetes. However, it is important to note that international data on diabetes are of varying quality and variations within regions and countries can exist. In 1993, Karvonen et al. reported that incidence rates in Europe varied from 4.6 per 100,000 in the northern regions of Greece to 30.2 per 100,000 in Sardinia. Authors of the Diabetes Atlas from which data for Table 3.6 were extracted note that data are compiled from multiple studies about childhood

onset diabetes (IDF 2000). Therefore data should be interpreted cautiously and considered general indicators only.

Table 3.6: Incidence of Type 1 diabetes in 0-14 year olds: selected countries, 2000

Region ^(a) and country	New cases per 100,000	Population 0-14 years ('000s)
Australia	18.7	3,979
New Zealand	15.0	862
Europe	10.3	140,720
Albania (lowest rate in Europe)	3.0	1,152
Germany	13.0	13,889
United Kingdom	18.0	11,513
Finland (highest rate in Europe)	45.0	993
North America	12.2	109,010
Mexico (lowest rate in North America)	0.6	37,646
United States of America	16.0	59,909
Canada (highest rate in North America)	20.0	6,454
Eastern Mediterranean and Middle East	5.6	197,311
Pakistan	5.0	70,880
Egypt	7.0	26,732
Africa	1.5	242,277
Tanzania (lowest rate in Africa)	0.8	16,240
Zimbabwe (highest rate in Africa)	2.0	5,581
South and Central America	5.7	136,142
Peru (lowest rate in South and Central America)	1.0	9,468
Puerto Rico (highest rate in South and Central America)	18.0	1,339
Asia	5.0	422,324
Republic of Korea (lowest rate in Asia)	0.7	11,363
Bangladesh (highest rate in Asia)	5.0	54,708

⁽a) Regions largely reflect those used by the International Diabetes Foundation (IDF).

Sources: Diabetes Atlas 2000 (IDF 2000) and National Diabetes Register for Australia.

Geographical location

A major area of research interest in diabetes is whether geographic influences manifest themselves in a change in incidence patterns of diabetes. Although three years of data are not sufficient to produce statistically significant findings for most areas, some Statistical Divisions did show differences in yearly cases when compared to other rates within the same state, the overall state rate or the national rate (Table 3.7):

- Hunter Statistical Division had a significantly higher rate (27.2 cases per 100,000 population) than the overall New South Wales rate of 19.1 cases per 100,000 population and the national rate of 19.4.
- The Sydney incidence (16.7 per 100,000 population) was significantly below the national incidence rate (19.4 per 100,000 population).

Incidence estimates for the Northern Territory and outback Queensland and Western Australia are low but should be treated cautiously as levels of ascertainment are considered low and may affect results.

Table 3.7: New cases of Type 1 diabetes among 0-14 year olds: Statistical Divisions, 1999-2001

Statistical Division ^(a)	NDR cases	Population ^(b)	Yearly cases (per 100,000 population)	95% CI
New South Wales				
Sydney	402	802,675	16.7	15.1–18.3
Hunter	97	119,442	27.2	21.8–32.5
Illawarra, Central West, South Eastern, Murrumbidgee	127	194,787	21.8	18.0–25.5
Richmond-Tweed, Mid-north Coast, Northern	86	142,186	20.2	16.0–24.5
Murray, Far West, North Western	42	57,621	24.2	16.9–31.5
New South Wales	755	1,316,711	19.1	17.7–20.5
Victoria				
Melbourne	366	663,699	18.4	16.5–20.3
Barwon, Central Highlands	49	80,712	20.3	14.6–26.0
Western District, Wimmera, Mallee	30	52,890	18.8	12.0–25.5
Loddon, Goulburn	54	77,972	22.9	16.8–29.1
Ovens-Murray, East Gippsland, Gippsland	50	71,951	23.1	16.7–29.5
Victoria	548	947,224	19.3	17.7–20.9
Queensland				
Brisbane	202	331,855	20.3	17.5–23.1
Moreton	81	137,211	19.7	15.4–24.0
Wide Bay-Burnett, Darling Downs, Fitzroy	102	140,110	24.3	19.6–29.0
Mackay, Northern	36	74,856	15.9	10.7–21.2
South West, Central West, Far North, North West	24	69,402	11.6	7.0–16.2
Queensland	445	753,434	19.7	17.9–21.5

(continued)

Table 3.7 (continued): New cases of Type 1 diabetes among 0–14 year olds: Statistical Divisions, 1999-2001

Statistical Division ^(a)	NDR cases	Population ^(b)	Yearly cases (per 100,000 population)	95% CI
South Australia				
Adelaide	135	203,238	22.1	18.4–25.9
Outer Adelaide, Yorke & Lower North, Murray Lands, South East, Eyre, Northern	54	88,226	20.2	14.8–25.7
South Australia	189	291,464	21.6	18.5–24.7
Western Australia				
Perth	174	276,095	21.0	17.9–24.1
South West, Lower Great Southern, Upper Great Southern, Midlands	46	73,076	21.0	14.9–27.0
South Eastern, Central, Pilbara, Kimberley	17	48,660	11.6	6.1–17.2
Western Australia	237	397,831	19.9	17.3–22.4
Tasmania				
Greater Hobart	31	39,311	26.0	16.8–35.2
Southern, Northern, Mersey- Lyell	30	59,469	17.0	11.0–23.1
Tasmania	61	98,780	20.6	15.4–25.8
Northern Territory				
Northern Territory	10	50,857	6.6	2.5–10.6
Australian Capital Territory				
Australian Capital Territory	40	64,067	20.8	14.4–27.3
Australia	2,285	3,922,183	19.4	18.6–20.2

⁽a) Statistical Divisions are as at 30 June 2000 (ABS 2001a-h).

⁽b) Australian population at 30 June 2000.

4. Persons with insulin-treated diabetes excluding Type 1

This chapter describes the characteristics of NDR registrants who have insulin-treated diabetes, excluding those with Type 1 diabetes. These include persons with insulin-treated diabetes in the following categories:

- Type 2
- Gestational
- Other types of diabetes excluding Type 1 (see Glossary).

It is important to note that these statistics may be somewhat unreliable due to consent rates of less than 80%.

4.1 Age and sex

Features of persons with insulin-treated diabetes, excluding Type 1, were as follows:

- There were 7,682 males and 8,285 females with insulin-treated diabetes other than Type 1, which represents just over 70% of all NDR registrants (Table 4.1).
- Males and females had a reported type of 'other' (see Glossary), in 2.2% and 1.7% of registrants, respectively.
- Almost 80% of registrants with Type 2 diabetes began to use insulin at or after 50 years of age.
- Gestational diabetes occurs during pregnancy, hence 86.6% of females with gestational diabetes first used insulin between the ages of 25 and 39 years.

Table 4.1: NDR registrants with insulin-treated diabetes, excluding Type 1: derived $^{(a)}$ type, by age at first insulin use and sex, 1999–2001

Age at first	Туре	2	Gestatio	onal	Other	(b)	Tota	I
insulin use	No.	%	No.	%	No.	%	No.	%
Males								
0–14	13	0.2	n.a.	n.a.	14	8.2	27	0.4
15–24	38	0.5	n.a.	n.a.	10	5.9	48	0.6
25–39	398	5.4	n.a.	n.a.	32	18.8	435	5.7
40–49	974	13.3	n.a.	n.a.	31	18.2	1,026	13.4
50-59	1,849	25.3	n.a.	n.a.	35	20.6	1,922	25.0
60–69	2,057	28.1	n.a.	n.a.	30	17.6	2,135	27.8
70–79	1,526	20.8	n.a.	n.a.	13	7.6	1,596	20.8
80 and over	467	6.4	n.a.	n.a.	5	2.9	493	6.4
Total males	7,322	100.0	n.a.	n.a.	170	100.0	7,682	100.0
Females								
0–14	12	0.2	0	0.0	23	16.1	35	0.4
15–24	74	1.2	120	7.2	15	10.5	209	2.5
25–39	636	10.1	1,435	86.6	26	18.2	2,101	25.4
40–49	772	12.3	102	6.2	14	9.8	904	10.9
50-59	1,373	21.8	_	0.0	19	13.3	1,427	17.2
60–69	1,564	24.9	_	0.0	27	18.9	1,630	19.7
70–79	1,291	20.5	_	0.0	17	11.9	1,359	16.4
80 and over	563	9.0	_	0.0	2	1.4	620	7.5
Total females	6,285	100.0	1,657	100.0	143	100.0	8,285	100.0

⁽a) There were 190 males and 200 females for whom a derived diabetes type could not be calculated due to missing date of first injection or missing date of diagnosis. These are included in the total.

4.2 Geographical location

The geographical distribution of NDR registrants with insulin-treated diabetes excluding Type 1 is presented in Table 4.2.

⁽b) See Glossary for 'Other types of diabetes'.

Table 4.2: NDR registrants with derived $^{(a)}$ insulin-treated diabetes (excluding Type 1): diabetes type, age at first insulin use and geographical location, 1999–2001

Age at first insulin use	Type 2	Gestational	Other	Total
		Capital city		
0–39	726	1,104	78	1,914
40–59	3,038	87	64	3,244
60–79	3,887	_	49	4,035
80 and over	635	_	3	680
Total persons—number	8,286	1,191	194	9,872
Total persons—per cent	83.9	12.1	2.0	100.0
		Other metropol	itan	
0–39	84	130	10	225
40–59	351	3	9	376
60–79	595	_	8	621
80 and over	95	_	2	107
Total persons—number	1,126	133	29	1,329
Total persons—per cent	84.7	10.0	2.1	100.0
		Large rural cen	tres	
0–39	79	95	10	183
40–59	317	4	8	335
60–79	414	_	5	437
80 and over	78	_	1	80
Total persons—number	888	99	24	1,035
Total persons—per cent	85.8	9.5	2.3	100.0
		Small rural cent	tres	
0–39	81	59	7	148
40–59	364	_	8	383
60–79	505	_	9	535
80 and over	86	_	_	93
Total persons—number	1,036	59	25	1,160
Total persons—per cent	89.3	5.1	2.1	100.0
		Other rural & rer	mote	
0–39	201	168	15	385
40–59	897	8	11	941
60–79	1,037	_	15	1,091
80 and over	136	_	1	153
Total persons—number	2,271	176	42	2,571
Total persons—per cent	88.3	6.8	1.6	100.0

(continued)

Table 4.2 (continued): NDR registrants with derived $^{(a)}$ insulin-treated diabetes (excluding Type 1): diabetes type, age at first insulin use and geographical location, 1999–2001

Age at first insulin use	Type 2	Gestational	Other	Total
		Total Australi	a	
0–39	1,171	1,555	120	2,855
40–59	4,968	102	99	5,279
60–79	6,438	_	87	6,720
80 and over	1,030	_	7	1,113
Total persons—number	13,607	1,657	313	15,967
Total persons—per cent	85.2	10.4	2.0	100.0

⁽a) There were 190 males and 200 females for whom a derived diabetes type could not be calculated due to missing date of first injection or missing date of diagnosis; these are included in the totals and therefore sub-components do not add to totals.

5. Mortality

All NDR records for 1999 to 2001 were matched against the AIHW National Death Index (NDI). In the years 1999 to 2001, there were 1,229 registrants identified as having died (Table 5.1). This represents just over 5% of all registrants on the Register. More than 90% of deaths occurred in registrants aged 50 years and over, suggesting that the majority of deaths were for people with Type 2 diabetes.

When interpreting the mortality statistics in this chapter, it should be noted that consent for participation in the NDR is only about 70% in the age groups above 40 years and therefore the true number of deaths of persons with insulin-treated diabetes is significantly understated.

Table 5.1: NDR	registrants:	deaths,	1999-2001
----------------	--------------	---------	-----------

	Males		Females		Persons	
Age at death	Number	Per cent	Number	Per cent	Number	Per cent
0–49	50	6.8	32	6.4	82	6.7
50–59	96	13.2	52	10.4	148	12.0
60–69	156	21.4	84	16.8	240	19.5
70–79	244	33.4	168	33.7	412	33.5
80 and over	184	25.2	163	32.7	347	28.2
All ages	730	100.0	499	100.0	1,229	100.0

5.1 Mortality rates

Age-standardised death rates were calculated for NDR registrants who died during 1999, 2000 and 2001 (Table 5.2). The main findings were as follows:

- For males who died during their first year of insulin use, the age-standardised death rates were 2,953 per 100,000 registrants in 1999; 2,591 in 2000 and 2,966 in 2001.
- This rate of mortality in the first year of insulin use was roughly 4 times higher than for males in the general population.
- For male registrants who were alive after the first year of insulin use, the age-standardised death rate dropped to around 2,000 per 100,000 registrants in both 2000 and 2001 for those in their second year of insulin use, about 2.8 times higher than for males in the general community.
- For male registrants alive after the second year of insulin use, the age-standardised death rate fell further in the third year of insulin use to about 1,500 per 100,000 registrants, in 2001.
- For female registrants, the age-standardised death rates were lower than for males. In the first year of insulin use, the age-standardised death rates for females were 1,458, 1,831 and 1,619 per 100,000 registrants in 1999, 2000 and 2001 respectively. This is between 3 and 4 times higher than for the general community.

• By the third year of insulin use, the age-standardised death rate for females had fallen to 1,131 per 100,000 registrants, 2.4 times higher than for the general population.

It is important to note that these data are based on only three years of collection and an ascertainment level in the older age groups of around 70%. Further analyses and confirmation of trends should be possible in the future as additional years of data are added and an improved level of ascertainment is achieved.

Table 5.2: NDR registrants: average annual age-standardised death rates,(a) 1999-2001

	1999		2000		2001	2001		
Year commenced insulin use	death rate per dea		Age- standardised death rate per 100,000 registrants	Ratio ^(c)	Age- standardised death rate per 100,000 registrants Ra			
			Males					
1999	2,953	4.0	2,048	2.9	1,476	2.1		
2000			2,591	3.6	1,944	2.7		
2001					2,966	4.2		
			Female	s				
1999	1,458	3.0	1,599	3.4	1,131	2.4		
2000			1,831	3.9	1,246	2.6		
2001					1,619	3.4		

⁽a) The indirect method of standardisation is used (see Chapter 6).

5.2 Cause of death

Cause of death information is available for most deaths occurring in 1999 and 2000. As at June 2002, the National Death Index contained information on underlying causes (see Glossary) and associated causes of death recorded on the death certificate for calendar years up to 2000. Up to 20 causes of death can be coded on the certificate. Causes of death are classified according to the international statistical classification of diseases and related health problems ICD-10 (WHO 1992).

Features of cause of death data for NDR registrants (persons with insulin-treated diabetes only) were as follows (Table 5.3):

- 46.9% of females had diabetes included as a cause of death on the death certificate compared with 38.2% of males.
- Neoplasms were the most common underlying cause of death.
- Ischaemic heart disease and cancer of the pancreas (15.5% of deaths and 11.0% of deaths respectively) were the most commonly recorded single causes of death.
- 9.9% of males died due to cancer of the bronchus and lung compared with 3.3% of females

⁽b) 1999 Australian death rates used in calculation of standardised mortality ratio (AIHW National Mortality Database).

⁽c) 2000 Australian death rates used in calculation of standardised mortality ratio (AIHW National Mortality Database).

⁽d) 2000 Australian death rates used in calculation of standardised mortality ratio (AIHW National Mortality Database). Number of deaths for Australia for 2001 were not available until after production of this report.

• 8.1% of females died from diseases of the respiratory system compared with 4.8% of males.

Table 5.3: NDR registrants: underlying causes of death for deceased registrants, 1999-2000

		Males			Female	es
Underlying cause of death	No.	%	% with diabetes on death certificate	No.	%	% with diabetes on death certificate
Neoplasms	140	47.8	23.6	86	41.1	24.4
Cancer of the pancreas	32	10.9	12.5	23	11.0	13.0
Cancer of the bronchus and lung	29	9.9	37.9	7	3.3	42.9
Diseases of the circulatory system	73	24.9	45.2	55	26.3	58.2
Ischaemic heart disease	46	15.7	60.9	32	15.3	59.4
Cerebrovascular diseases Diabetes mellitus	12 29	4.1 9.9	33.3 100.0	12 25	5.7 12.0	50.0 100.0
	29	9.9	100.0	25	12.0	100.0
Diseases of the respiratory system	14	4.8	35.7	17	8.1	41.2
All other diseases	37	12.6	35.1	26	12.4	50.0
Total	293	100.0	38.2	209	100.0	46.9

Note: Results refer only to those registrants for whom an underlying code of death was available.

Source: AIHW National Death Index.

The coding of multiple causes of death on a death certificate allows for a more comprehensive picture of what other conditions present may have contributed to the death (see Glossary). For both males and females, diabetes was recorded as an associated condition in over half of deaths due to ischaemic heart disease. In contrast, only 13% of deaths due to cancer of the pancreas had diabetes recorded as an associated cause.

It should be noted that the preceding statistics are in respect of persons with insulin-treated diabetes and that differences in the mortality patterns for those with Type 1 diabetes compared with those with other types of diabetes have not been examined. This is because of clinical problems in distinguishing between persons with Type 1 and Type 2 diabetes aged 40 years and over. As the Register matures in future years, it may be possible to examine the mortality patterns of persons with Type 1 diabetes separately.

6. Statistical notes

6.1 Calculation of age at diagnosis

The method used to derive age at diagnosis depends on whether the data are sourced from NDSS or APEG.

NDSS records

Age at diagnosis = date of diagnosis - date of birth

APEG records

Age at diagnosis = first injection date - date of birth

Diagnosis date is not available for most APEG records, but first injection date for children diagnosed with Type 1 diabetes is considered to be the same as diagnosis date.

6.2 Derivation of diabetes type

The following algorithm agreed by the NDR Management Committee and published in the first statistical report on the Register is used to assist in obtaining a more accurate measure of the type of diabetes. The purpose of this formula is to re-classify registrants believed to be incorrectly recorded as having Type 1 diabetes rather than Type 2. Records of registrants reporting Type 2 diabetes, gestational diabetes or other types of diabetes were excluded from this derivation. For further background information on this algorithm, please see the *National Diabetes Register, Statistical Profile, December 2000* (AIHW 2001:13).

For persons reporting Type 1 only:

If age at diagnosis is missing or age at diagnosis is less than or equal to 35 years, then diabetes type = 1.

If age at diagnosis is over 35 years and the difference between the year of diagnosis with diabetes and the year of first insulin use is greater than 2 years, then diabetes type = 2.

If the age at diagnosis is over 35 years and the difference between the year of first insulin use and the year of diagnosis with diabetes is less than or equal to 2 years, then diabetes type = 1.

Note: If the year of first insulin use is missing, the year of first syringe purchase is used as a proxy for year of first insulin use.

6.3 Age-standardised rates

Age-standardisation is a technique used to eliminate the effect of differences in population age structures when comparing rates for different periods of time, and/or different geographic areas and/or different population sub-groups. Definitions are included in the National Health Data Dictionary (AIHW 2002b).

There are two methods of age-standardisation, direct and indirect. Tables in this report have been footnoted to identify which method was used.

Direct age-standardisation

To control for any effects of varying age structures of population, direct age-standardisation is used to calculate rates. The 1991 Australian population was used as the standard population in calculating age-standardised rates, using the following formula (Armitage et al. 2002):

$$SR = \frac{\sum (RiPi)}{\sum Pi}$$

where SR = standardised rate, Ri = the age-specific rate for age group i for the population being studied, and Pi = the Australian standard population (persons) as at 30 June 1991 for age group i.

Indirect age-standardisation

The indirect method is recommended for use when calculating rates for small populations where fluctuations in age-specific rates can affect the reliability of rates calculated using the direct method (Armitage et al. 2002). The formula is as follows:

$$SR = \frac{C}{\sum (RiPi)} \times R$$

where SR = standardised rate, C is the actual number of cases in the population being studied, Ri = the age-specific rate of the standard population for age group i, Pi = the population age group i for the population being studied, R = crude rate of the standard population.

6.4 Mortality rates

Mortality rates for both the Register population and total Australia were calculated using the indirect standardisation formula (see Section 6.3 above). However, an adjustment was made to the Register's annual standardised mortality rates to account for the average period that the population was on the Register and therefore exposed to the risk of death.

For example, for registrants who joined the Register in 1999, the average period was only 0.37 of a year, reflecting a relatively lower rate of registrations in the first half of 1999. If registrants had joined the Register evenly throughout 1999 (as they did in 2000 and 2001), the average time spent on the Register in that year would have been 0.5 of a year.

The adjusted standardised mortality rates for the Register population were obtained by multiplying the standardised mortality rate by the inverse of the average period of time that the Register population was exposed to the risk of death as a registrant. In the case of the 1999 death rate, the adjustment factor was 2.70, that is 1/0.37.

6.5 Confidence intervals

The 95% confidence intervals in this report indicate the variation that might be expected in incidence numbers purely by chance. The confidence intervals are calculated using the following formula, which has been adapted from that presented in AIHW & AACR (2002):

95% CI = R
$$\pm$$
 1.96 x $\sqrt{\frac{R}{\text{Number of cases}}}$

where R = average yearly cases (per 100,000 population).

7. Diabetes research

The Register is available for diabetes research. A package 'Access to the National Diabetes Register' is available on the AIHW web site at http://www.aihw.gov.au or alternatively, by contacting:

The Project Officer, National Diabetes Register Cardiovascular Disease, Diabetes and Risk Factor Monitoring Unit Australian Institute of Health and Welfare GPO Box 570 Canberra ACT 2601 Phone: (02) 6244 1000

Applications to access the Register for research will be considered only if the applicant provides assurance of scientific quality, evidenced either by the project having been funded through a competitive peer-reviewed grant process or by review by independent peers acceptable to the Institute.

Before a project can proceed, approval must be obtained from the investigator's host Ethics Committee and the AIHW Ethics Committee. Application forms for approval are a component of the above-mentioned research package.